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Gaucher disease (GD) type 1 is the most common lysosomal storage disease and the most common genetic disorder among Ashkenazi Jews. The majority of patients with GD present with unexplained splenomegaly and/or thrombocytopenia, and the disorder often affects children; consequently, haematologists and paediatricians are ideally placed to diagnose this condition. Prompt 
management of GD type 1 using enzyme-replacement therapy or substrate reduction therapy can reduce the risk of developing long-term 
GD complications and reverse many of the initial signs/symptoms, thereby improving both quality and duration of life. Treatment is most 
effective when initiated early; consequently, a prompt diagnosis is essential. Despite this, the average time to diagnosis following the onset 
of clinical symptoms is 4 years. Reasons for the delay include the heterogeneous nature of the disease, together with a lack of awareness of 
rare haematological disorders and the benefits of early treatment. Indeed, studies show that only 20% of haematologists consider GD type 
1 in their differential diagnosis for patients presenting with splenomegaly and/or thrombocytopenia. To help raise awareness of GD, reduce 
the diagnostic delay and prevent unnecessary tissue biopsies, simple diagnostic algorithms and screening tools have been developed and 
validated, both in adults and in children.
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Diagnosis is often delayed in patients with Gaucher disease type 1
Case 1
A 37-year-old Caucasian woman with spherocytosis reported since childhood presented with 
swollen ankles, gradually increasing abdominal girth, sudden weight gain (3 kg in 6 days), 
fatigue and exertional dyspnoea. Patient history showed delayed growth during childhood, 
hepatosplenomegaly from 3 years of age (resulting in an incorrect diagnosis of spherocytosis) 
and a severe sport-related fracture of the humerus with humeral head necrosis. No alcohol 
abuse, liver disease/hepatitis, blood coagulation abnormalities or prothrombotic diseases were 
reported. The first of the patient’s two pregnancies resulted in post-partum bleeding requiring a 
blood transfusion. 
Physical examination revealed pallor, hepatosplenomegaly and oedema in both legs, which resolved 
with diuretics (a sign of portal hypertension). Blood examination showed leucopenia (1,730/mm3), 
thrombocytopenia (92,000/mm3) and normochromic, normocytic anaemia (haemoglobin [Hb] 
7.8 g/dl, mean corpuscular volume [MCV] 90.1 fl) with mildly increased ferritin (352 ng/ml). 
Transferrin saturation (TSAT), serum iron levels, haemolytic indices, folate/vitamin B12 and renal 
and liver function were normal. Autoimmune, virological and neoplastic diseases were excluded. 
Blood smear and osmotic globular resistance tests excluded spherocytosis. 
Splenomegaly (diameter 18 cm) and hepatic stiffness (7.4 KPa; normal value <5 KPa) consistent with 
stage 1 fibrosis were confirmed. Liver disease (but not Gaucher disease [GD]) was suspected and 
therefore a liver biopsy was performed. Significant portal and lobular infiltration with aggregated 
CD68-positive polygonal cells and granulated cytoplasm was observed, with no iron overload. 
GD was suspected at this point. Further tests showed significantly elevated chitotriosidase 
activity (14,290 nmol/h/ml; normal value <100), low β-glucosidase activity (28 nmol/h/mg; normal 
range 200–500) and the identification of β-glucosidase (GBA) gene mutations, all of which led 
to a diagnosis of GD type 1. Treatment with enzyme replacement therapy (ERT) led to improved 
laboratory parameters after 1 year. The patient is currently well and continues to receive ERT with 
no side effects.
The (mis)diagnosis of spherocytosis disguised the patients’ clinical manifestations of GD from 
childhood to adult life, thereby exposing her to an inappropriate liver biopsy and delaying 
appropriate management.
DOI: https://doi.org/10.17925/EOH.2018.14.1.50
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Case 2
A 15-month-old child presented with persistent fever, cough and 
mild respiratory distress. Initial tests showed hepatosplenomegaly, 
leukocytosis with lymphocytosis (white blood cell count [WBC] 
30,130/μl; L 73%), microcytic anaemia (Hb 8 g/dl; MCV 63 fl), 
thrombocytopenia (114,000/μl) and increased C-reactive protein (CRP; 
10.8 mg/dl; normal volunteers <0.5 mg/dl). The child was admitted to 
the paediatric ward with a suspected infection and was treated with 
cefotaxime three times daily. 
The patient’s medical history revealed growth delays from 6 months of 
age, previous hospital admissions for fever and a urinary tract infection, 
normal neurological development (other than a minor speech delay) 
and no pathological eye movements. Serological and microbiological 
tests were positive for cytomegalovirus (CMV), but negative for 
lymphoproliferative disease and Epstein Barr virus. Reduced TSAT (4%) 
with mildly increased ferritin levels suggested that microcytic anaemia 
was partially related to iron deficiency. Haemolytic indices were normal.
Fever and respiratory distress gradually improved, CRP levels normalised 
and CMV infection resolved. However, hepatosplenomegaly persisted 
(spleen length, 10.9 cm) and anaemia associated with fluctuating, mild 
thrombocytopenia (113,000–190,000/μl) did not improve after oral iron 
therapy. A bone marrow aspirate showed no signs of haematological 
disease; however, a diagnosis of GD could not be excluded based on 
this finding.
The combination of growth retardation, anaemia, thrombocytopenia and 
hepatosplenomegaly suggested a lysosomal storage disease (LSD). A 
dried blood spot (DBS) test showed reduced β-glycosidase activity and 
molecular analysis detected a homozygous mutation in the GBA gene 
(c.1226A>G/c.1226A>G; N370S/N370S). GD type 1 was diagnosed and 
ERT was prescribed. Anaemia and thrombocytopenia resolved after 
3 months; hepatosplenomegaly and growth parameters improved up to 
1-year post-treatment, with no side effects.
Gaucher disease
GD is a rare, autosomal recessive disorder caused by mutations in the 
GBA gene (GBA1; EC 3.2.1.45).1–7 More than 330 mutations have been 
identified to date, all of which result in reduced levels of the enzyme, 
which in healthy individuals hydrolyses glucosylceramide into ceramide 
and glucose. GD is characterised by an accumulation of sphingolipids – 
primarily glucosylceramide and glucosylsphingosine – in macrophages 
and other reticuloendothelial cells, leading to the formation of ‘Gaucher 
cells’ (Figure 1). These lipid-laden cells gradually infiltrate the spleen, 
liver, kidneys, lung, brain and/or bone marrow causing progressive and 
heterogeneous disease. Although rare, GD is the most common type 
of LSD, with an estimated prevalence of 1/75,000 births among the 
general population, rising to 1/600 births among Ashkenazi Jews.5 
GD encompasses a continuum of phenotypes ranging from a perinatal 
lethal form (type 2) to a mild or asymptomatic adult form (type 1).8 The 
vast majority of patients with GD type 1 present with haematological 
complications, including spontaneous bruising/bleeding due to 
thrombocytopenia and/or GD-associated coagulopathy, abdominal 
discomfort/swelling due to splenomegaly and/or chronic fatigue 
due to anaemia.2,4,8–10 Other symptoms, including hepatomegaly and 
abnormal liver function, increased susceptibility to infection due to 
suboptimal neutrophil function and neutropenia, pulmonary disease, 
bone pain and (in children) growth retardation and/or delayed puberty 
may also be present. 
GD type 1 (Online Mendelian Inheritance in Man® [OMIM®] number 
230800) – the most common and mildest form of the disorder – is usually 
distinguished from types 2 and 3 (OMIM numbers 230900 and 231000, 
respectively) by the absence of neurological symptoms. In patients 
with GD types 2 and 3, these include convulsions, hypertonia, mental 
retardation, apnoea, slow saccades and/or dementia.4,6,11 However, the 
distinction between GD types is not always clear. For example, peripheral 
neuropathies and neurological symptoms resulting from spinal 
compression fractures have been reported in patients with GD type 1 and 
a higher incidence of Parkinsonism has recently been associated with 
mutations in the GBA1 gene.12,13 Conversely, the neuropathic symptoms 
associated with GD type 3 may be mild, with many patients graduating 
from college and leading a relatively normal life.14
Long-term complications associated with GD type 1 include pulmonary 
hypertension,15 haematological malignancies (leukaemia, multiple 
myeloma and lymphoma), and — less frequently — solid cancers 
(e.g. hepatocellular carcinoma, melanoma and pancreatic cancer).16–19 
Skeletal disorders due to bone marrow infiltration (e.g. pathological 
fractures, osteolytic lesions and osteonecrosis) are also common 
and may be associated with a significantly reduced quality of life.2,3,20 
Prognosis varies depending on GD type, organ involvement, symptom 
severity and time from symptom-onset to treatment. In general, patients 
with GD type 1 who remain untreated survive through to adulthood, 
whereas those with GD type 2 (<1% of patients) die within the first 
Figure 1: A: Bone marrow aspiration and B: Trephine biopsy, 
both with May-Greunwald-Giemsa stain
A
B
Images reproduced with permission from Dr Jesús Villarrubia.
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few years of life, and those with type 3 (<5%) survive into early (and 
sometimes late) adulthood.4,6,8 
The usual treatment for GD type 1 is ERT using macrophage-targeted 
recombinant β-glucosidase (imiglucerase [Cerezyme®; Sanofi Genzyme, 
Cambridge, MA, US], velaglucerase alfa [VPRIV; Shire, Lexington, MA, 
US] and, in some European countries, taliglucerase alfa [Elelyso®; 
Protalix Biotherapeutics and Pfizer, New York, NY, US).2,10,21 ERT acts by 
augmenting deficient β-glucosidase activity via intravenous infusions 
of functional enzyme and has been proven safe and effective for 
preventing and/or reversing many of the symptoms associated with 
GD. The magnitude and speed of response to ERT largely depend on the 
individual patient’s clinical characteristics, symptom severity and rate 
of disease progression.21 Of particular note is the limited response to 
ERT in patients with GD-associated malignancies and its lack of effect 
on neurological symptoms. Another therapeutic approach is to use 
substrate reduction therapy (SRT) such as miglustat (Zavesca®; Actelion 
Pharmaceuticals, San Francisco, CA, US) or eliglustat (Cerdelga®; Sanofi 
Genzyme, Cambridge, MA, US), which can alleviate non-neurological 
GD symptoms by reducing glucocerebroside production.2 In Europe 
and the USA, eliglustat is approved as a first-line therapy for adults 
with GD type 1 who, based on CYP2D6 genotyping, are predicted to be 
extensive, intermediate, or poor metabolisers. This constitutes >90% of 
patients with GD type 1.21 Miglustat is indicated for the oral treatment of 
adult patients with mild to moderate type 1 Gaucher disease and may 
be used only in the treatment of patients for whom ERT is unsuitable.
The importance of an early diagnosis and prompt 
management
Prompt treatment of GD type 1 with ERT can prevent or reverse many 
of the clinical features associated with this condition, thereby improving 
quality of life.1,3,9,20,22–29 For example, a study of 884 patients with GD type 
1 found that, when initiated during childhood, 8 years’ continuous 
treatment with ERT was associated with the normalisation/near-
normalisation of Hb levels, platelet count, liver and spleen volumes, and 
mean bone mineral density z-score, with significant reductions in the 
incidence of bone crises.24 Conversely, a study in 17 patients with GD 
with delayed diagnosis (up to 10 years) found that approximately 25% 
developed irreversible complications including avascular bone necrosis, 
severe bleeding, chronic bone pain, life-threatening sepsis, pathologic 
fractures, growth failure and liver pathology.30 In addition to enabling 
effective management strategies, a prompt diagnosis of GD enables 
early screening of at-risk relatives and the timely provision of genetic 
counselling for affected individuals and their families/carers.
Despite the importance of early symptom management, people with 
GD often experience considerable diagnostic delays.30–32 Most patients 
with early GD symptoms are initially referred to a haematologist 
and/or paediatrician.32 However, a survey of 406 haematologist–
oncologists from seven countries found that only 20% of physicians 
included GD in their differential diagnosis of patients with classic GD 
symptoms, with most suspecting leukaemia, lymphoma or multiple 
myeloma.30 Of the 136 patients followed in this survey, the average 
time from symptom development to diagnosis was 4.1 ± 10.3 years. 
According to a retrospective review of 86 GD cases from a single centre, 
19% of patients experienced diagnostic delays of longer than 5 years.31 
Perhaps surprisingly, the Gaucher Outcomes Study (GOS) found that, of 
the 1,209 participants with diagnosed GD, at least 174 (14.4%) patients 
remained untreated.9 Whereas some of these patients may have had 
mild or absent symptoms that (physicians believed) did not warrant 
expensive pharmacological treatments, others may not have had access 
to required medications. Nonetheless, results suggest that management 
delays in patients with GD might be confounded by a lack of awareness 
regarding the benefits of prompt treatment. 
Diagnostic clues 
Approximately 60% of patients with GD type 1 have thrombocytopenia at 
diagnosis and 86% (and 95% of children)8 have splenomegaly.30 Suspicion 
of GD should be further raised by the presence of hepatomegaly, fatigue 
(sometimes related to anaemia), leucopenia, bone pain/disease, growth 
retardation and/or delayed puberty.8,10 
Care should be taken to distinguish GD from conditions that 
present with similar features, such as other lipid storage disorders 
(e.g. Niemann–Pick disease, Tay–Sachs disease and Pompe disease), 
haematological malignancies (e.g. leukaemia, lymphoma and multiple 
myeloma), immune thrombocytopenic purpura, autoimmune disease, 
hepatic cirrhosis, idiopathic avascular necrosis, viral disease, idiopathic 
splenomegaly and anaemia of chronic disease.10,31 The presence of 
hepatomegaly and polyclonal gammopathy without neutropenia can 
be useful for distinguishing GD from haematological malignancies. 
However, malignancy and GD sometimes co-exist and therefore further 
tests are required.
Diagnostic tests
β-glucosidase activity tests
A definitive diagnosis of GD can be obtained by measuring 
β-glucosidase activity in peripheral blood leucocytes (normal range: 
2.1–5.3 μmol/l/h33).4,8,10 However, this test is only conducted at specialised 
centres, and diagnosis is often delayed by large distances between test 
centres and hospitals. Although blood samples can be couriered to test 
centres, they must be analysed almost immediately. This is not always 
possible without prior booking. Consequently, the β-glucosidase assay 
might not be performed during the initial visit. 
To accelerate the diagnostic process, two cost-effective, non-invasive 
DBS assays have been developed for screening β-glucosidase activity.35 
The benefit of these assays is that samples can be posted to a test 
centre via regular mail and stored until required. Both the tandem 
mass spectroscopy (MS/MS) DBS assay36 and the fluorescence DBS 
assay37 utilise a synthetic substrate instead of the native substrate, 
and both are associated with a low risk of false negative results. 
However, the fluorescence assay yields a relatively high rate of false 
positives;35,38 consequently, positive results must be followed up using 
the traditional assay.
Mutation analysis
Molecular screening for common GBA1 mutations is a cheap, reliable 
test for Ashkenazi Jews and other individuals who are at high risk for 
GD.4,8,10 In other populations, this technique may be complicated by a 
number of factors: 
• It is not always possible to distinguish mutations in the active gene 
from those in the highly homologous pseudogene.
• A negative screen for common mutations does not exclude GD.
• The correlation between genotype and phenotype is weak. 
Bone marrow biopsy
Bone marrow biopsy is useful for distinguishing haematological 
malignancy from GD, but should not be the first choice in Ashkenazi 
Jews and is rarely recommended in children due to the invasive 
nature of the test.4,8,10 Moreover, the presence of Gaucher cells in bone 
marrow (Figure 1) is not necessarily diagnostic of GD, because ‘pseudo’ 
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Gaucher cells are often associated with other conditions (Table 1).39 
Conversely, failure to detect Gaucher cells in a bone marrow aspirate 
cannot be used to exclude GD. 
Biochemical markers
Abnormal levels of one or more biochemical markers (Table 2) are 
suggestive of GD; however, results are generally not sufficient to diagnose 
GD because similar changes can be caused by other disorders.40–42 
The most reliable and specific biomarker for GD identified to date is 
glucosylsphingosine (lyso-GL1).43,44 
Algorithms for the diagnosis of Gaucher disease 
type 1
Diagnostic algorithms designed to increase physician awareness of 
GD, prevent unnecessary biopsies and shorten the time from symptom 
development to diagnosis/management have been validated both in 
adults10 and in children.8 A diagnostic algorithm has also been developed 
for children suspected of having an LSD.45 
Gaucher disease diagnosis in adults
Given the relative incidence of GD type 1 versus haematological 
malignancy in the Ashkenazi Jewish population – approximately 1/800 
versus 1/2,500 – algorithms for the diagnosis and management of 
GD in adults suggest that β-glucosidase activity should be routinely 
assessed in all high-risk individuals with thrombocytopenia and 
splenomegaly (Figure 2A).10 The GD diagnostic test should also be 
performed in patients without splenomegaly, but with one or more 
of the following: thrombocytopenia, bleeding tendency, unexplained 
stable hyperferritinaemia with normal TSAT and/or increased levels of 
inflammatory markers. Invasive tests, such as bone marrow biopsies, 
are not necessary and should be avoided in this population. 
In people not descended from Ashkenazi Jews, splenomegaly is 
more likely to be caused by haematological malignancy than by GD 
(incidence 40/100,000 versus 1/40,000–100,000).10 In these patients, 
it is reasonable to perform a bone marrow biopsy before GD is 
considered to rule out malignancy (and other conditions associated 
with splenomegaly, such as portal hypertension due to liver diseases, 
haemoglobinopathies and chronic haemolytic anaemias) (Figure 2B). 
When interpreting biopsy results, it is important to remember that 
malignancy and GD sometimes co-exist,15 that Gaucher-like cells 
(Figure 1) are not exclusive to GD (Table 1) and that a diagnosis of GD 
should not be excluded if Gaucher cells are not found in patients with 
other signs/symptoms of GD.8
Although splenectomy is indicated for a number of conditions 
associated with splenomegaly, it tends to worsen the clinical course 
Table 1: Conditions in which Gaucher-like cells may occur in 
bone marrow39
Hodgkin lymphoma (World Health Organization Classification)
Non-Hodgkin lymphoma
Chronic myelogenous leukaemia
Acute or chronic lymphocytic leukaemia
Multiple myeloma
Congenital dyserythropoeietic anaemia, type II
Thalassaemia
Hereditary sea-blue histiocytosis
‘Hairy cell’ leukaemia
Table 2: Common laboratory markers in Gaucher 
disease8,10,40,41,43,44
Elevated Decreased
Glucosylsphingosine (lyso-GL1) Clotting factors
Chitotriosidase Vitamin B12
CCL18 Total cholesterol
ACE Platelet count (sometimes below 
20x109/l)
TRAP
Ferritin
Lysozyme
Polyclonal gammopathy and/or MGUS
ACE = angiotensin-converting enzyme; CCL18 = chemokine (C-C motif) ligand; 
MGUS = monogammopathy of unknown significance; TRAP = tartrate-resistant acid 
phosphatase.
Figure 2: Algorithm for the diagnosis of Gaucher disease in 
A: adults descended from Ashkenazi Jews and B: adults not 
descended from Ashkenazi Jews 
Please note: Although not mentioned in the treatment algorithm provided by Mistry et 
al., a diagnosis of GD in Ashkenazi Jews can be made by mutation analysis as well as 
by enzyme analysis. Reproduced with permission from Mistry et al., 2011.10 
GD = Gaucher disease; MGUS = monoclonal gammopathy of unknown significance; 
TSAT = transferrin saturation.
A
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of GD in the liver, skeleton and the lungs.46 Consequently, GD must be 
excluded in all patients being considered for splenectomy. Assessment 
of splenomegaly should be combined with an examination of spleen 
parenchyma using abdominal ultrasound or magnetic resonance 
imaging. In patients with GD, the incidence of focal splenic defects 
caused by collections of Gaucher cells is approximately 20%, with 
incidence increasing with spleen size.47
Gaucher disease diagnosis in children/young adults
Algorithms for the diagnosis and management of GD (types 1 and 3) in 
children/young adults propose that GD should be considered in all children 
with unexplained splenomegaly, with or without thrombocytopenia, 
anaemia and/or hepatomegaly (Figure 3).8 
Where possible, GD should be confirmed using a β-glucosidase assay, 
thereby avoiding unnecessary emotional trauma and/or bleeding that 
might be caused by bone marrow biopsy or liver biopsy.8 A DBS assay 
is recommended in children with unexplained splenomegaly, with or 
without hepatomegaly, who have thrombocytopenia and/or anaemia 
and at least one of the following: 
• eye movement disorders (strabismus and/or oculomotor apraxia),48 
• growth deceleration or retardation (occurs in 34% of children 
with GD),49
• the Erlenmeyer flask deformity (EFD; a skeletal deformity present in 
49% of children with GD),49 and/or 
• elevated levels of ferritin and tartrate-resistant acid phosphatase 
(TRAP). 
Although bone pain is reported in 27% of patients with early GD,25 the 
subjective nature of pain excludes it as a reliable criterion.
In children with splenomegaly without thrombocytopenia or anaemia, 
a diagnosis of malignancy should be considered before testing for GD.8 
If findings from a detailed medical history, physical examination and 
first-line laboratory tests do not suggest malignancy, an immediate 
enzyme assay is warranted. If malignancy is suggested, a bone marrow 
Figure 3: Algorithm for the diagnosis of Gaucher disease in the paediatric population
No
NoYes
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± hepatomegaly
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Other causes of
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 infectious
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(including metabolic
disease other
than GD)
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present?
Assess the presence of the following:
•  Erlenmeyer ash deformity (if Rx available)
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Enzyme
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Reproduced with permission from Di Rocco et al., 2014.8  
GD = Gaucher disease; Rx = prescription; TRAP = tartrate-resistant acid. 
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aspirate/biopsy should be performed. Metabolic diseases, including GD, 
should be considered in the absence of blood disorders, malignancy 
or infection (e.g. visceral leishmaniasis), even if Gaucher cells are not 
found in the aspirate. 
In all cases, a diagnosis of GD should be followed by mutation analysis 
to determine the causative GBA1 mutation, thereby predicting the most 
likely GD type and the most appropriate management strategy.
Impact of implementing diagnostic algorithms and 
simple diagnostic tools
A survey of 16 medical experts from 14 GD specialist centres across 
12 countries found that the main causes of diagnostic delay in patients 
with GD are a lack of awareness of GD/misdiagnosis (54% of experts), 
followed by phenotypic heterogeneity/non-specific symptoms (23%), 
mild symptomatology (15%) and outsourced testing (8%).32 Moreover, a 
survey of 406 haematologist–oncologists found that <50% of physicians 
were aware that the enzyme assay is the most appropriate diagnostic 
test for GD type 130 and a retrospective evaluation of 86 GD type 1 cases 
found that, despite clear guidelines discouraging the use of invasive 
procedures in people with suspected GD, the majority of patients had 
been diagnosed via bone marrow biopsy.31 It therefore follows that the 
implementation of simple diagnostic algorithms and the development 
of rapid diagnostic tools, such as the DBS assay, will avoid the need for 
unnecessary biopsies, reduce diagnostic delays and enable prompt 
(more effective) GD management.
To test this hypothesis, a study conducted in 35 haematology 
outpatient units across Italy was designed to estimate the prevalence 
of GD type 1 among 196 non-Ashkenazi Jewish adults (61 females, 
135 males; mean age 47.8 ± 18.2 years) with splenomegaly and/or 
thrombocytopenia, diagnosed using the algorithm described by 
Mistry et al. (Figure 2).10 Patients were tested for β-glucosidase 
enzyme activity using the fluorescence-based DBS assay and, where 
possible, positive results were confirmed using the traditional assay 
and molecular GBA1 analysis. Overall, 34 of the 196 patients had 
a DBS value <4.4 pmol/punch/h (17.35%), and one patient had a 
negative DBS result despite a family history of GD. Overall, 7 patients 
(3.6% [95% confidence interval: 1.4–7.2] of the overall population; 1/28 
patients) tested positive for GD using the β-glucoside activity assay, 
10 (5.1%) were not available for follow up and 18 (9%) were GD-negative. 
To put these results into context, an initial survey showed that 18% 
of patients attending the same clinics each year had splenomegaly 
and/or thrombocytopenia, and that, using traditional diagnostic 
procedures, 11% of this subgroup never received a diagnosis. This 
suggests that the combined use of a diagnostic algorithm and DBS 
assay facilitates GD diagnosis and might reduce diagnostic delays 
among adults with splenomegaly and/or thrombocytopenia. A similar 
study – the GAUcher disease in Paediatric patients (GAU‐Ped) study – 
is ongoing in 53 paediatric haematology and oncology centres across 
Italy, using the diagnostic algorithm developed for children/young 
adults and the fluorescence-based DBS assay.8 
Summary
Early diagnosis and prompt management of GD has the potential to 
reduce the risk of long-term GD complications while reversing many 
of the initial signs/symptoms. Most patients with GD have unexplained 
splenomegaly and/or thrombocytopenia, and many present during 
childhood; consequently, the majority of initial referrals are to 
haematologists and/or paediatricians.32 These physicians often fail to 
consider GD in their differential diagnosis due to a lack of awareness of 
rare haematological disorders, phenotypic heterogeneity and/or mild or 
non-specific symptoms.31 Diagnostic delays have also been attributed to 
expensive, time-consuming, outsourced testing. 
Studies conducted in adults across Italy suggest that the use of simple 
diagnostic algorithms and newly-available DBS assays facilitate the 
diagnosis of GD and avoid unnecessary biopsies, even among physicians 
without disease-specific expertise.42 Although not definitive, evidence 
suggests that this may lead to a reduction in the diagnostic delay, thereby 
enabling prompt management and subsequent improvements in both 
clinical outcome and quality of life. Greater efforts are needed to raise 
awareness about the benefits of prompt GD diagnosis and management 
among non-GD experts.9 q
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